Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03533816 · ClinicalTrials.gov registry record · Phase 1
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
A Phase 1 study, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03533816 is a Phase 1 study that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 38 participants.
The verdict
NCT03533816, a Phase 1 study, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).
Interventions
- DRUG EAGD T-cell infusion (Phase I)
- DRUG EAGD T-cell infusion (Expansion)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-01-31 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03533816
The ClinicalTrials.gov registry entry for NCT03533816 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EAGD T-cell infusion (Phase I) is the first listed.
NCT03533816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03533816 about?
NCT03533816 is a clinical study titled "Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide". Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partiall...
What is the current status of trial NCT03533816?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2020-01-31. Estimated completion is 2028-01.
What interventions are being tested in trial NCT03533816?
The interventions under investigation include: EAGD T-cell infusion (Phase I) (DRUG), EAGD T-cell infusion (Expansion) (DRUG).
Who is sponsoring clinical trial NCT03533816?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.